Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ovid Therapeutics Inc. OVID
$3.58
+$0.05 (1.42%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
251761027.00000000
-
week52high
3.70
-
week52low
1.41
-
Revenue
1502748
-
P/E TTM
-5
-
Beta
1.13044900
-
EPS
-0.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Neutral | Neutral | 20 мая 2022 г. |
| Citigroup | Neutral | Neutral | 25 авг 2021 г. |
| Cantor Fitzgerald | Neutral | Overweight | 20 апр 2021 г. |
| JMP Securities | Market Perform | Market Outperform | 02 дек 2020 г. |
| Citigroup | Neutral | Buy | 02 дек 2020 г. |
| Citigroup | Neutral | Neutral | 29 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tardio Jason | D | 0 | 17344 | 12 сент 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 1250 | 1250 | 01 июл 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 0 | 1250 | 01 июл 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 5750000 | 5750000 | 01 июл 2022 г. |
| TAKEDA PHARMACEUTICAL CO LTD | A | 0 | 1250 | 01 июл 2022 г. |
| Bernstein Karen | A | 69424 | 69424 | 08 апр 2022 г. |
| Duncan Barbara Gayle | A | 21347 | 21347 | 08 апр 2022 г. |
| Perone Thomas Michael | A | 10000 | 10000 | 08 апр 2022 г. |
| Perone Thomas Michael | A | 25399 | 25399 | 08 апр 2022 г. |
| Rona Jeffrey A | A | 10000 | 10000 | 08 апр 2022 г. |
Новостная лента
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
05 мая 2023 г. в 09:54
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.23 per share a year ago.
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
12 апр 2023 г. в 13:42
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
GlobeNewsWire
10 апр 2023 г. в 08:00
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
GlobeNewsWire
09 мар 2023 г. в 08:00
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participant in a fireside chat at the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023 at 4:00 p.m. ET.
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
GlobeNewsWire
02 дек 2022 г. в 10:00
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.